AMERICAN OUTCOMES MANAGEMENT

Your Choice for Home Infusion - IVIG Referral Fax Line: 800-528-9860

ACHC ACCREDITED

Product Specifics:	Bivigam	Cutaquig	Gammagard Liquid	Gammagard S/D	Gammaked / Gamunex-C	Gammaplex	Hizentra	Hyqvia	Octagam	Panzyga	Privigen
Sizes	5g, 10g	1g, 1.65g, 2g, 3.3g, 4g, 8g	1g, 2.5g, 5g, 10g, 20g, 30g	5g, 10g	1g, 2.5g, 5g, 10g, 20g	5g, 10g, 20g	1g, 2g, 4g, 10g	2.5g, 5g, 10g, 20g, 30g	5%: 1g, 2.5g, 5g, 10g 10%: 2g, 5g, 10g, 20g	10%: 2.5g, 5g, 10g, 20g, 30g	5g, 10g, 20g, 40g
Storage	Refrigerate between 2 to 8° C (36 to 46°F) Do not freeze or heat. Do not shake.	Refrigerate between 2 to 8° C (36 to 46°F) Do not freeze or heat. Do not shake.	2° to 8°C (36°to 46°F) Do not freeze. Do not shake.	Not to exceed 25°C (77°F), Avoid freezing. Do not shake.	2° to 8°C (36°to 46°F). Do not freeze.	Room temperature (25°C) (77°F) - 36 months Do not freeze. Do not shake.	Room temperature (25°C) (77°F) Do not freeze. Keep vials in storage box until use.	Refrigeration: 2° to 8°C (36° to 46°F) for 36 mths. Room temperature (25°C) (77°F) for up to 3 mths during the 1st 24 mths from Mfg date. Protect from light. Do not freeze.	2° to 8°C (36° to 46°F) for 24 months. Do not freeze.	2° to 8°C (36° to 46°F) for 24 months. Or room temperature for 9 months. Do not freeze.	Room temperature (25°C) (77°F) Protect from light. Do not freeze. Do not shake.
Form	Liquid	Liquid	Liquid	Lyophilized	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid
Reconstitution Fluid	N/A	N/A	N/A	Sterile Water for Injection	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Concentration Options	10%	16.5%	10%	5% or 10%	10%	5% and 10%	20%	10%	5% and 10%	10%	10%
Indications	PI	PI	PID + MMN	PID + ITP + CLL + Kawasaki disease	PID + ITP + CIDP	PI and ITP	PID/CIDP	PI	5%: PID 10%: ITP	PID & ITP	PID + ITP/CIDP
Contraindications	History of anaphylactic or severe systemic reactions to human immunoglobulin. IgA deficient patients with antibodies against IgA and a history of hypersensitivity.	History of anaphylactic or severe systemic reactions to human immunoglobulin or other components of Cutaquig. IgA deficient patients with antibodies against IgA and a history of hypersensitivity.	History of anaphylactic or severe systemic reactions to human immunoglobulin. IgA deficiency with antibodies to IgA	Selective IgA deficiency where IgA deficiency is only abnormality of concern.	IgA deficiency with antibodies to IgA	History of anaphylactic or severe systemic reactions to human immunoglobulin. IgA deficient patients with antibodies against IgA and a history of hypersensitivity.	IgA deficiency with antibodies to IgA. Also contraindicated in hyperprolinemia patients due to stabilizer: L-proline.	History of anaphylactic or severe systemic reactions to human immunoglobulin. IgA deficient patients with antibodies against IgA and a history of hypersensitivity. Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of Hyqvia. Known systemic hypersensitivity to human albumin (in the hyaluronidase solution).	IgA deficiency with antibodies to IgA History of anaphylactic or severe reactions to human immunoglobulin	IgA deficiency with antibodies to IgA History of anaphylactic or severe reactions to human immunoglobulin	IgA deficiency with antibodies to IgA. Also contraindicated in hyperprolinemia patients due to stabilizer: L-proline.
Infusion Rates (Refer also to full prescribing information).	Initial: 0.5mg/kg/min for the first 10 minutes Maintenance Infusion Rate (if tolerated): Increase every 20 minutes by 0.8mg/kg/min up to 6mg/kg/min.	First 6 infusions: 15-20mL/per hour/per site Subsequent infusions: 25mL per hour/per site as tolerated Maximum recommended flow rates per hour for all sites combined: First 6 infusions: 30mL/per hour/all sites combined Infusion 7 onwards: gradual increase to 50mL per hour/all sites combined, subsequently to 80mL per hour for all sites combined, and if tolerated a further gradual increase up to 100mL per hour for all sites combined may be possible.	Intravenous (IV): Initial: 0.8mg/kg/min Maximum: 8-9mg/kg/min Subcutaneous (SC): Initial: 1.37 x current IV dose in mg/kg per IV dose interval in weeks Maximum: 20 to 30mL/hr/site	Use a 5% solution at 0.5 mL/kg/hr. Patients who tolerate the 5% solution at up to 4 mL/kg/hr can be infused with 10% solution starting at 0.5 mL/kg/hr up to 8 mL/kg/hr.	Intravenous (IV): Initial: 1mg/kg/min Maximum: 8mg/kg/min Subcutaneous (SC): Initial: 1.37 x current IV dose in mg/kg per IV dose interval in weeks Maximum: 20mL/hr/site	5%: Initial: 0.5mg/kg/min (0.01 mL/kg/min) for 15 mins, increase gradually every 15 mins to 4mg/kg/min (0.08mL/kg/min) 10%: Initial: 0.5mg/kg/min (.005mL/kg/min) for 15 mins, Increase gradually every 15 mins to 8mg/kg/min (0.08 mL/kg/min)	Subcutaneous only: Not for intravenous administration. Injection sites: abdomen, thighs, upper arms, and/or lateral hip. Initial Infusion: 15mL/hr/inj site. Subsequent infusions may be increased as tolerated to 25mL/hr/site at a maximum rate of 50mL/hour for all sites combined.	1st 2 Infusions: <88lbs 5mL per site, per hour ramping up 5mL every 5-15 minutes, max 80mL per site, per hour. >88lbs 10mL per site, per hour ramping up every 5-15 minutes, max 240mL per site, per hour. Subsequent 2 or 3 infusions: <88lbs 10mL per site, per hour ramping up 5mL every 5-15 minutes, max 160mL per site, per hour. >88lbs 10mL per site, per hour ramping up every 5-15 minutes, max 300mL per site per hour.	5% Initial: 0.01mL/kg/minute (0.5mg/kg/minute) Maintenance infusion rate: 3.33gm/kg/min (if tolerated) 10% Initial: 1.0mg/kg/min Maximum: Up to 12.0mg/kg/min	PID Initial: 1mg/kg/minute Maximum rate for new PID patient: 8mg/kg/min Maximum rate for experienced PID patients: 12 or 14mg/kg/min ITP Initial: 1mg/kg/min Maximum Rate: 8mg/kg/min	Initial:0.5mg/kg/min Maximum: 4mg/kg/min
Other Administration Information	Allow refrigerated product to come to room temperature before infusing.	Do not dilute. Vials are single use only. Discard any unused product after infusion in accordance with local requirements.	If dilution is required, may be diluted with 5% dextrose in water (D5/W). Warm to room temperature before infusing.	If refrigerated, warm to room temperature prior to infusion.	If dilution is required, may be diluted with 5% dextrose in water (D5/W). May be pooled in either glass or plastic. Warm to room temperature prior to infusion.	Infuse product at approximately room temperature. Infuse with set preferable fitted with an in-line 15-20 micron filter.	Warm to room temperature. Discard unused product immediately after use.	Warm to room temperature. Do not shake. Administer components of Hyqvia sequentially. Do not use either component alone.	Warm to room temperature if refrigerated prior to infusion.	Warm to room temperature.	If dilution is required, may be diluted in 5% dextrose in water (D5/W).
Compatibility Issues	Do not dilute. Infuse using a separate line by itself, without mixing with other intravenous fluids or medications the patient may be receiving.	Do not mix with other products.	Infuse product by separate line without mixing other IV fluids or medications. Do not use NS 0.9% as a diluent.	Administer separately from other drugs/medications.	Infuse product by separate line without mixing with other IV fluids or medications. If administered through indwelling catheter, flush with D5W or NS before and after infusing product.	Administer separately from other drugs/medications.	Should not be mixed with other medicinal products.	Do not mix the hyaluronidase and Hyqvia in the same container prior to administration. Do not mix Hyqvia with other products.	Administer separately from other drugs or medications. Flushing: any normal infusion solution (i.e. D5W/saline).	Administer separately from other drugs or medications.	Infuse product by separate line without mixing other medications or fluids.
IgA Content	≤200 µg/mL	<0.6 mg of IgA / mL	37 µg/mL	≤2.2 µg/mL (5% concentration)	46 µg/mL	5%: <10 µg/mL 10%: <20 µg/mL	≤50mcg/mL	37 µg/mL	5%: <200 µg/mL 10%: <106 µg/mL	On average product contains 100 µg/mL	≤25 mcg/mL
Sugar Content	No sugar; stabilized with glycine	Maltose 79mg/mL	No sugar; stabilized with glycine.	2% glucose (5% concentration)	No sugar; stabilized with glycine.	5%: D-Sorbitol 10%: no sugar; stabilized with Glycine	No sugar; stabilized with l-proline.	No sugar; stabilized with glycine.	5%: Maltose 100mg/mL 10%: Maltose 90mg/mL	No sugar; stabilized with glycine.	No sugar; stabilized with a nonessential amino acid: 250 mmol/L L-proline
Sodium Content	.100-0.140 M Sodium Chloride	≤30mmol/L	None detected	Approximately 8.5 mg/mL sodium chloride	Trace amounts	5%: 30-50mmol/L 10%: <30mM Sodium Chloride	Trace Amounts	None detected	≤30 mmol/L	Trace amounts	Trace amounts
Osmolarity / Osmolality	370-510 mOsm/kg	310-380 mOsmol/kg	240-300 mOsmol/kg	636 mOsmol/L (5%) 1250 mOsmol/L (10%)	258 mOsmol/kg	5%: 420-500 mOsm/kg 10%: 240-280 mOsmol/kg	380 mOsmol/kg	240-300 mOsmol/kg	310-380 mOsmol/kg	240-310 mOsmol/kg	320 mOsmol/kg (240 to 440 range)
Latex in product stopper	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free
Latex in diluent stopper	N/A	N/A	N/A	Contains Latex	N/A	N/A	N/A	N/A	N/A	N/A	N/A